Clinical trials of new treatments for Fragile X are accepting participants

Published March 22, 2012 in FRAXA Research Foundation

Experimental new drugs, AFQ056 (an mGluR5 antagonist from Novartis) and STX209 (arbaclofen from Seaside Therapeutics) are in large scale trials.

Clinical trials of new treatments for Fragile X are accepting participants

Filed under: , , ,